Market Cap 90.53M
Revenue (ttm) 0.00
Net Income (ttm) -39.83M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.13
Volume 401,200
Avg Vol 1,032,236
Day's Range N/A - N/A
Shares Out 34.69M
Stochastic %K 14%
Beta 1.51
Analysts Strong Sell
Price Target $18.20

Company Profile

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washing...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 210 2217
Address:
22722 29th Dr. SE, Suite 100, Bothell, United States
LarryEllisonsmoustache
LarryEllisonsmoustache Jul. 31 at 9:05 PM
$ACHV , this stock acts funny after hours pretty often
2 · Reply
NVDAMillionaire
NVDAMillionaire Jul. 29 at 7:29 PM
$ACHV Outstanding article that hits the mark on ACHV's current state. So if you want to refresh your ACHV insights or learn about ACHV from scratch, this is a must read. https://beyondspx.com/article/achieve-life-sciences-cytisinicline-poised-to-reshape-nicotine-dependence-treatment-achv
2 · Reply
bobtheknob
bobtheknob Jul. 29 at 12:36 PM
$ACHV Rick Stewart, Chief Executive Officer of Achieve, will participate in a fireside chat with Julian Harrison, BTIG Biotechnology Analyst, on Tuesday, July 29, at 3:20 pm EDT
2 · Reply
MrTicker
MrTicker Jul. 29 at 12:30 PM
$ACHV SEATTLE and VANCOUVER, British Columbia, July 29, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc.(ACHV) , a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that the company will participate in the BTIG Virtual Biotechnology Conference being held July 29-30, 2025. Rick Stewart, Chief Executive Officer of Achieve, will participate in a fireside chat with Julian Harrison, BTIG Biotechnology Analyst, on Tuesday, July 29, at 3:20 pm EDT. For more information or to register for the conference, please email BTIG at [email protected].
0 · Reply
MrTicker
MrTicker Jul. 29 at 12:30 PM
$ACHV Achieve Life Sciences to Participate in the BTIG Virtual Biotechnology Conference GLOBENEWSWIRE 7:30 AM ET 7/29/2025
1 · Reply
DistributionEquity
DistributionEquity Jul. 28 at 9:32 PM
$ACHV Here's another:
0 · Reply
bobtheknob
bobtheknob Jul. 23 at 10:57 AM
$ACHV FDA’s artificial intelligence is supposed to revolutionize drug approvals. It’s making up studies https://amp.cnn.com/cnn/2025/07/23/politics/fda-ai-elsa-drug-regulation-makary
2 · Reply
DistributionEquity
DistributionEquity Jul. 22 at 4:04 PM
$ACHV Place yer bets!
3 · Reply
They_call_me_tater_salad
They_call_me_tater_salad Jul. 22 at 2:16 PM
$ACHV Today $REPL is down 75% following FDA rejection of a new drug application. This FDA response (“not adequate/well‑controlled”) screams a shift: single‑arm or loosely controlled studies are out, even with sick populations. Randomized, double‑blind, placebo‑controlled (RCT) is the new minimum bar. ACHV is built for this environment: • 2 full randomly controlled Phase 3s (ORCA‑2/3; n>1,600) hit p<0.0001 on validated continuous‑abstinence endpoints. • ORCA‑OL added long‑term safety only because FDA asked in ’23—now delivered with no SAEs. • Gap: no new Rx quit aid since 2006; Chantix gone. Unmet need still huge despite HHS shakeups. • CMC: Sopharma dispute noted, but alternates are embedded in the NDA to backstop supply risk. Bottom line: If FDA is demanding gold‑standard RCT evidence, ACHV already has it. If you wonder how we are built for the new FDA then understand we are built for them.
3 · Reply
They_call_me_tater_salad
They_call_me_tater_salad Jul. 22 at 12:09 AM
$ACHV Published in October 2024 in The Annals of Internal Medicine. The FDA and National Institute of Health jointly expressing that there is an urgent and unmet need for new and better smoking cessation treatments. Anyone know THE company bringing an option to the table? https://nida.nih.gov/news-events/news-releases/2024/10/nih-and-fda-leaders-call-for-innovation-in-development-of-smoking-cessation-treatments
1 · Reply
Latest News on ACHV
LarryEllisonsmoustache
LarryEllisonsmoustache Jul. 31 at 9:05 PM
$ACHV , this stock acts funny after hours pretty often
2 · Reply
NVDAMillionaire
NVDAMillionaire Jul. 29 at 7:29 PM
$ACHV Outstanding article that hits the mark on ACHV's current state. So if you want to refresh your ACHV insights or learn about ACHV from scratch, this is a must read. https://beyondspx.com/article/achieve-life-sciences-cytisinicline-poised-to-reshape-nicotine-dependence-treatment-achv
2 · Reply
bobtheknob
bobtheknob Jul. 29 at 12:36 PM
$ACHV Rick Stewart, Chief Executive Officer of Achieve, will participate in a fireside chat with Julian Harrison, BTIG Biotechnology Analyst, on Tuesday, July 29, at 3:20 pm EDT
2 · Reply
MrTicker
MrTicker Jul. 29 at 12:30 PM
$ACHV SEATTLE and VANCOUVER, British Columbia, July 29, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc.(ACHV) , a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that the company will participate in the BTIG Virtual Biotechnology Conference being held July 29-30, 2025. Rick Stewart, Chief Executive Officer of Achieve, will participate in a fireside chat with Julian Harrison, BTIG Biotechnology Analyst, on Tuesday, July 29, at 3:20 pm EDT. For more information or to register for the conference, please email BTIG at [email protected].
0 · Reply
MrTicker
MrTicker Jul. 29 at 12:30 PM
$ACHV Achieve Life Sciences to Participate in the BTIG Virtual Biotechnology Conference GLOBENEWSWIRE 7:30 AM ET 7/29/2025
1 · Reply
DistributionEquity
DistributionEquity Jul. 28 at 9:32 PM
$ACHV Here's another:
0 · Reply
bobtheknob
bobtheknob Jul. 23 at 10:57 AM
$ACHV FDA’s artificial intelligence is supposed to revolutionize drug approvals. It’s making up studies https://amp.cnn.com/cnn/2025/07/23/politics/fda-ai-elsa-drug-regulation-makary
2 · Reply
DistributionEquity
DistributionEquity Jul. 22 at 4:04 PM
$ACHV Place yer bets!
3 · Reply
They_call_me_tater_salad
They_call_me_tater_salad Jul. 22 at 2:16 PM
$ACHV Today $REPL is down 75% following FDA rejection of a new drug application. This FDA response (“not adequate/well‑controlled”) screams a shift: single‑arm or loosely controlled studies are out, even with sick populations. Randomized, double‑blind, placebo‑controlled (RCT) is the new minimum bar. ACHV is built for this environment: • 2 full randomly controlled Phase 3s (ORCA‑2/3; n>1,600) hit p<0.0001 on validated continuous‑abstinence endpoints. • ORCA‑OL added long‑term safety only because FDA asked in ’23—now delivered with no SAEs. • Gap: no new Rx quit aid since 2006; Chantix gone. Unmet need still huge despite HHS shakeups. • CMC: Sopharma dispute noted, but alternates are embedded in the NDA to backstop supply risk. Bottom line: If FDA is demanding gold‑standard RCT evidence, ACHV already has it. If you wonder how we are built for the new FDA then understand we are built for them.
3 · Reply
They_call_me_tater_salad
They_call_me_tater_salad Jul. 22 at 12:09 AM
$ACHV Published in October 2024 in The Annals of Internal Medicine. The FDA and National Institute of Health jointly expressing that there is an urgent and unmet need for new and better smoking cessation treatments. Anyone know THE company bringing an option to the table? https://nida.nih.gov/news-events/news-releases/2024/10/nih-and-fda-leaders-call-for-innovation-in-development-of-smoking-cessation-treatments
1 · Reply
ZacksSCR
ZacksSCR Jul. 21 at 4:24 PM
Zacks SCR Summer of Submissions July 2025 $ACHV $GRCE $CING $MDAI https://youtu.be/Ha0u0n87afc?si=AU2b2Ug9jeSg7YWp
2 · Reply
RunningRobert1
RunningRobert1 Jul. 21 at 1:09 PM
$ACHV ACHV Stock: Bullish or Bearish for 2025? https://youtu.be/UYNKyV-ioJc A general summary of the company looking at both the bullish and bearish parts of it. This fits with companies that can double or triple, late stage positive trials along with an approval in site for 2026
0 · Reply
LarryEllisonsmoustache
LarryEllisonsmoustache Jul. 19 at 11:54 PM
$ACHV , Grok saying 60-70% chance of success
4 · Reply
mikejohns777
mikejohns777 Jul. 18 at 12:10 PM
$INTS Pump → dilute → dump → reverse split → repeat Want to know the future of this stock? Ask $ACHV holders.
2 · Reply
succeeds
succeeds Jul. 17 at 2:00 PM
2 · Reply
InquisitorD
InquisitorD Jul. 16 at 11:34 PM
$ACHV https://d1io3yog0oux5.cloudfront.net/achievelifesciences/sec/0002052113-25-002528/0002052113-25-002528.pdf
3 · Reply
Futurision
Futurision Jul. 16 at 10:38 PM
My portfolio share as of yesterday was $SRPT 30% $SGMO 30% $OMER 15% $ACHV 15% $NTLA 10% So congrats to all of us and on a a continued ride like this 🚀 Major $SGMO jump next when Fabry Deal is announced
6 · Reply
bestdriver7
bestdriver7 Jul. 16 at 2:20 PM
$ACHV hi guys
0 · Reply
ted_the_trader
ted_the_trader Jul. 16 at 1:02 PM
1 · Reply
Supermoto87
Supermoto87 Jul. 16 at 1:44 AM
$ACHV Reminder: "...smoking remains the leading cause of preventable death in the United States. CDC data show that smoking causes more than 480,000 deaths annually, with an estimated 41,000 deaths from secondhand smoke exposure, and it can reduce a person’s life expectancy by 10 years. It also creates a significant economic burden. In 2018, smoking had an estimated economic impact of $600 billion, including more than $240 billion in health care spending." That's a rate of more than 1,300 Americans dying every day, and significant contribution to the national debt. HHS has a moral obligation and duty to the American people to prioritize cytisinicline for smoking cessation. If not, what the hell are they doing and what is theirmission? https://www.aamc.org/news/smoking-still-leading-cause-preventable-death-us-doctors-may-soon-have-new-tools-help-people-quit
1 · Reply
knowing123
knowing123 Jul. 15 at 5:37 PM
$ACHV what is the gap for achv ?
1 · Reply
Raxothus
Raxothus Jul. 15 at 3:54 PM
EOD FOLLOW-UP – 07/15/25 Tracking continuation watch from 07/14 based on today’s highs vs prior close ✅ $YHC – Closed 3.16, hit 3.82 HOD, broke over 3.80 and held trend ❌ $DDC – Closed 20.15, hit 15.02 HOD, full rejection and fade ✅ $IOBT – Closed 1.75, hit 1.90 HOD, clean follow-through on steady trend ❌ $ACHV – Closed 2.61, hit 2.61 HOD, no breakout, flat and weak ❌ $EPIX – Closed 1.86, hit 1.87 HOD, no movement despite prior volume Recap Total: 5 Winners: 2 Faders: 3 Accuracy: 40% Choppy continuation day Only $YHC and $IOBT gave clean follow-through $DDC and $ACHV both rejected hard or stayed flat Volume confirmation still key — we don’t enter without it No volume, no entry. No reclaim, no reason. #VWAP #SniperSetup #Continuation #SmallCaps #Accountability #DayTrading
0 · Reply